Post-menopausal hormone replacement therapy, coronary heart disease and plasma lipoproteins.

摘要: This review outlines the changes in serum lipoprotein (Lp) concentrations at menopause. The effect of hormone replacement therapy with estrogen and a variety progestogens is illustrated by number recent studies. Analysis effects primary prevention coronary heart disease (CHD) discussed. During last 4 years, there have been observational studies use postmenopausal women CHD as assessed angiography. In all these studies, has associated reduction CHD, most strikingly study survival over 10 years. However, an overwhelming need for randomised controlled trial secondary prevention. role treatment type II hyperlipoproteinaemia recognised, describing its Again, data from well clinical trials to clearly establish benefits therapy. A further aspect investigation non-lipoprotein-mediated estrogen, particularly those on vasomotion. Finally, intriguing both androgenic estrogenic steroids Lp(a) are